PPD plans to spin off its compound partnering business from its core CRO business. The spin-off will result in two capitalized, highly focused, independent public companies, according to a PPD statement. The CRO business will continue to operate under the PPD name and will be focused solely on its drug discovery and development services. The compound partnering business will focus on developing and commercializing its drug candidates and to access external capital, if needed, without any cons...